<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">NCP</journal-id>
<journal-id journal-id-type="hwp">spncp</journal-id>
<journal-id journal-id-type="nlm-ta">Nutr Clin Pract</journal-id>
<journal-title>Nutrition in Clinical Practice</journal-title>
<issn pub-type="ppub">0884-5336</issn>
<issn pub-type="epub">1941-2452</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0884533613487220</article-id>
<article-id pub-id-type="publisher-id">10.1177_0884533613487220</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Letters to the Editor</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Response</article-title>
<subtitle>Efficacy of Erythropoietin Combined With Enteral Nutrition for the Treatment of Anemia in Crohn’s Disease</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Liu</surname><given-names>Song</given-names></name>
<degrees>MD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Ren</surname><given-names>Jianan</given-names></name>
<degrees>MD, FACS</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Li</surname><given-names>Jieshou</given-names></name>
<degrees>MD</degrees>
</contrib>
</contrib-group>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2013</year>
</pub-date>
<volume>28</volume>
<issue>4</issue>
<fpage>523</fpage>
<lpage>523</lpage>
<permissions>
<copyright-statement>© 2013 American Society for Parenteral and Enteral Nutrition</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="society">The American Society for Parenteral and Enteral Nutrition</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<p>We appreciate the response expressed by the authors of the Letter to the Editor, who discussed the study we performed with enteral nutrition (EN) plus erythropoietin (EPO) in anemic patients with Crohn’s disease (CD).<sup><xref ref-type="bibr" rid="bibr1-0884533613487220">1</xref></sup> We agree that it is difficult to distinguish iron status using regular biochemical parameters (eg, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration) when inflammation exists, and evidence is unavailable from our study whether this combination therapy (EN plus EPO) can correct an iron deficiency condition in patients with CD. However, as stated in our study, the therapeutic efficacy of this therapy is principally determined by hemoglobin level, treatment success rate, and adverse events. With the fact that iron deficiency has become one of the main underlying reasons of anemia in CD (which has been confirmed by numerous previous studies),<sup><xref ref-type="bibr" rid="bibr2-0884533613487220">2</xref></sup> we assumed that a considerable proportion of patients in this study should have iron deficiency. Our main purpose was to investigate the ability to correct hemoglobin level and inflammatory condition with EN and EPO, instead of discussing the reason for anemia or iron status modification in these patients. The unique advantage of this combination therapy is that it provides an alterative option of oral iron supplementation (sustained-release and sustained-absorbed, elemental iron-containing EN), which provides effectiveness and convenience, avoids adverse effects (oxidative stress, intestinal inflammation, and even colorectal cancer), and decreases the intolerance rate of conventional oral iron supplementation.</p>
<p>We agree that the soluble receptor of transferrin (sTfR) is a reliable and useful parameter to evaluate iron status, especially under inflammatory conditions. Serum sTfR level can reflect both the tissue iron status (receptor density on cells) and EPO activity (number of cells with receptors).<sup><xref ref-type="bibr" rid="bibr3-0884533613487220">3</xref></sup> Therefore, it would be very interesting to employ sTfR in a study focusing on the influence of EPO on iron status in patients with CD.</p>
<p>Although there are some contrasting conclusions of the effect of EPO on inflammatory cytokines,<sup><xref ref-type="bibr" rid="bibr4-0884533613487220">4</xref></sup> Meng et al<sup><xref ref-type="bibr" rid="bibr5-0884533613487220">5</xref></sup> recently discovered that EPO could suppress the production of tumor necrosis factor–α and interleukin (IL)–6 in an animal experiment. This regulatory effect of EPO is to some extent in accordance with our study, in which we confirmed a decreased level of C-reactive protein after EN plus EPO treatment. Indeed, other studies also reported an immunomodulatory effect of EPO, including inhibiting reactive dendritic cells (innate response), abrogating Th1 (interferon-γ) and Th17 (IL-6 and IL-17) polarization, and promoting Treg expansion.<sup><xref ref-type="bibr" rid="bibr6-0884533613487220">6</xref>,<xref ref-type="bibr" rid="bibr7-0884533613487220">7</xref></sup> Nevertheless, evidence of the role of EPO in the regulation of inflammatory responses in patients with CD is still not sufficient; further studies are therefore expected.</p>
<sig-block>
<sig>Song Liu, MD<break/><italic>Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing, China</italic><break/><italic>Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA</italic></sig>
<sig>Jianan Ren, MD, FACS<break/>Jieshou Li, MD<break/><italic>Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing, China</italic></sig>
</sig-block>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="bibr1-0884533613487220">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Liu</surname><given-names>S</given-names></name>
<name><surname>Ren</surname><given-names>J</given-names></name>
<name><surname>Hong</surname><given-names>Z</given-names></name><etal/>
</person-group>. <article-title>Efficacy of erythropoietin combined with enteral nutrition for the treatment of anemia in Crohn’s disease: a prospective cohort study</article-title>. <source>Nutr Clin Pract</source>. <year>2013</year>;<volume>28</volume>(<issue>1</issue>):<fpage>120</fpage>-<lpage>127</lpage>.</citation>
</ref>
<ref id="bibr2-0884533613487220">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gasche</surname><given-names>C</given-names></name>
<name><surname>Lomer</surname><given-names>MC</given-names></name>
<name><surname>Cavill</surname><given-names>I</given-names></name>
<name><surname>Weiss</surname><given-names>G</given-names></name>
</person-group>. <article-title>Iron, anaemia, and inflammatory bowel diseases</article-title>. <source>Gut</source>. <year>2004</year>;<volume>53</volume>(<issue>8</issue>):<fpage>1190</fpage>-<lpage>1197</lpage>.</citation>
</ref>
<ref id="bibr3-0884533613487220">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Speeckaert</surname><given-names>MM</given-names></name>
<name><surname>Speeckaert</surname><given-names>R</given-names></name>
<name><surname>Delanghe</surname><given-names>JR</given-names></name>
</person-group>. <article-title>Biological and clinical aspects of soluble transferrin receptor</article-title>. <source>Crit Rev Clin Lab Sci</source>. <year>2010</year>;<volume>47</volume>(<issue>5-6</issue>):<fpage>213</fpage>-<lpage>228</lpage>.</citation>
</ref>
<ref id="bibr4-0884533613487220">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cervellini</surname><given-names>I</given-names></name>
<name><surname>Sacre</surname><given-names>S</given-names></name>
<name><surname>Ghezzi</surname><given-names>P</given-names></name>
<name><surname>Mengozzi</surname><given-names>M</given-names></name>
</person-group>. <article-title>Erythropoietin does not affect TNF and IL-6 production directly</article-title>. <source>J Biol Regul Homeost Agents</source>. <year>2013</year>;<volume>27</volume>(<issue>1</issue>):<fpage>189</fpage>-<lpage>196</lpage>.</citation>
</ref>
<ref id="bibr5-0884533613487220">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meng</surname><given-names>R</given-names></name>
<name><surname>Zhu</surname><given-names>D</given-names></name>
<name><surname>Bi</surname><given-names>Y</given-names></name>
<name><surname>Yang</surname><given-names>D</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
</person-group>. <article-title>Erythropoietin inhibits gluconeogenesis and inflammation in the liver and improves glucose intolerance in high-fat diet-fed mice</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>(<issue>1</issue>):<fpage>e53557</fpage>.</citation>
</ref>
<ref id="bibr6-0884533613487220">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yuan</surname><given-names>R</given-names></name>
<name><surname>Maeda</surname><given-names>Y</given-names></name>
<name><surname>Li</surname><given-names>W</given-names></name>
<name><surname>Lu</surname><given-names>W</given-names></name>
<name><surname>Cook</surname><given-names>S</given-names></name>
<name><surname>Dowling</surname><given-names>P</given-names></name>
</person-group>. <article-title>Erythropoietin: a potent inducer of peripheral immuno/inflammatory modulation in autoimmune EAE</article-title>. <source>PLoS One</source>. <year>2008</year>;<volume>3</volume>(<issue>4</issue>):<fpage>e1924</fpage>.</citation>
</ref>
<ref id="bibr7-0884533613487220">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>SJ</given-names></name>
<name><surname>Wang</surname><given-names>YL</given-names></name>
<name><surname>Lo</surname><given-names>WT</given-names></name><etal/>
</person-group>. <article-title>Erythropoietin enhances endogenous haem oxygenase-1 and represses immune responses to ameliorate experimental autoimmune encephalomyelitis</article-title>. <source>Clin Exp Immunol</source>. <year>2010</year>;<volume>162</volume>(<issue>2</issue>):<fpage>210</fpage>-<lpage>223</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>